Clinical Report: Scaling Smarter with Continuous Manufacturing in Drug Development

Overview

Continuous manufacturing, particularly through twin-screw extrusion, enhances the scalability and precision of drug production. This approach mitigates risks associated with scale-up, ensuring consistent quality and reducing waste, which is crucial for the pharmaceutical industry.

Background

The transition from research and development (R&D) to pilot production in pharmaceuticals presents significant challenges, particularly in maintaining product quality and consistency. Continuous manufacturing technologies, such as twin-screw extrusion, offer solutions to these challenges by ensuring uniform processing conditions across different scales. This is increasingly important as the industry faces stricter regulations and a push for precision medicine.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Twin-screw extruders maintain consistent temperature, pressure, and shear rates during scale-up.
• Real-time monitoring of extrusion parameters improves product consistency and reduces variability.
• Continuous processes allow for a cost-effective 'scale-out' approach rather than traditional scale-up methods.
• Precision and repeatability in manufacturing are critical for patient safety and regulatory compliance.
• Advanced technologies like continuous granulation and 3D printing enhance efficiency and reduce processing steps.

Clinical Implications

Pharmaceutical manufacturers can leverage continuous manufacturing to improve the reliability of drug production while adhering to stringent regulatory standards. This approach not only enhances patient safety through consistent dosing but also optimizes the use of expensive active pharmaceutical ingredients.

Conclusion

The integration of continuous manufacturing technologies represents a significant advancement in drug development, addressing key challenges in scalability and quality control. This shift is essential for meeting the evolving demands of the pharmaceutical industry.

References

1. The Medicine Maker, 2026 -- Making – and Scaling – Advanced Medicines
2. The Medicine Maker, 2026 -- Manufacturability and the Winners in Advanced Therapies
3. The Medicine Maker, 2026 -- Manufacturing Inside the Patient
4. European Medicines Agency (EMA) -- ICH guideline Q13 on continuous manufacturing of drug substances and drug products
5. ScienceDirect -- Manufacturing process transfer to a 30 kg/h continuous direct compression line with real-time composition monitoring
6. the medicine maker — The Strategic Questions Reshaping the CDMO Map
7. ICH guideline Q13 on continuous manufacturing of drug substances and drug products - Scientific guideline | European Medicines Agency (EMA)
8. Manufacturing process transfer to a 30 kg/h continuous direct compression line with real-time composition monitoring - ScienceDirect
9. 17 March 2025